{"title":"Bulk Offers","description":"\u003cp\u003eOur most-requested peptides in \u003cstrong\u003e10-vial packs\u003c\/strong\u003e — built for high-volume research programs that need a consistent supply, batch after batch.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e10-vial packs\u003c\/strong\u003e — enough material for long-term, repeatable studies\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLower cost per vial\u003c\/strong\u003e than buying single units\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIn stock \u0026amp; ready\u003c\/strong\u003e — same-day dispatch on orders placed before 2 PM\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSame tested purity\u003c\/strong\u003e — every batch third-party verified, with a COA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eAll products are for Research Use Only (RUO). No fillers — just the peptide, verified for identity and purity.\u003c\/em\u003e\u003c\/p\u003e","products":[{"product_id":"bpc-157-tb-500-blend-5-mg-5-mg-10-vials","title":"BPC-157 + TB-500 Blend – 5 mg \/ 5 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}.qvg-desc-rt sup a:hover{color:#233137}\u003c\/style\u003e\n\u003cp\u003eThis blend pairs \u003cstrong\u003eBPC-157\u003c\/strong\u003e and \u003cstrong\u003eTB-500\u003c\/strong\u003e (5 mg each) — two of the most-studied repair peptides — chosen for their \u003cstrong\u003ecomplementary mechanisms\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBPC-157\u003c\/strong\u003e has shown localized effects on tendon, ligament and gut tissue and strong pro-angiogenic activity in preclinical models\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/japplphysiol.00945.2010\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTB-500\u003c\/strong\u003e (thymosin β4) drives systemic \u003cstrong\u003ecell migration and angiogenesis\u003c\/strong\u003e, accelerating endothelial migration several-fold in preclinical research\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1096\/fasebj.11.6.9194528\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFindings above come from preclinical (animal and cell-based) research on these molecules and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816106737891,"sku":"BB10-10","price":590.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-bpc-157-tb-500-5-mg-5-mg.png?v=1784485201"},{"product_id":"glow-blend-10-vials","title":"GLOW – 70 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}.qvg-desc-rt sup a:hover{color:#233137}\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eGLOW\u003c\/strong\u003e pairs three of the most-studied regenerative peptides — \u003cstrong\u003eGHK-Cu, BPC-157 and TB-500\u003c\/strong\u003e — for a skin-and-tissue blend that targets appearance and repair together.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGHK-Cu\u003c\/strong\u003e drives collagen\/elastin synthesis and, in controlled aged-skin studies, improved elasticity and reduced wrinkles\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1163\/156856208784909435\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBPC-157\u003c\/strong\u003e and \u003cstrong\u003eTB-500\u003c\/strong\u003e add the repair layer: in preclinical research BPC-157 accelerated tendon-cell migration\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/japplphysiol.00945.2010\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e and TB-500 (thymosin β4) drove endothelial migration and angiogenesis\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1096\/fasebj.11.6.9194528\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution. \u003cem\u003eFigures above summarize published cosmetic and preclinical research on these molecules and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107163875,"sku":"GLOW-10","price":840.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-glow-70-mg-centered-v2_6558775e-3a66-44aa-981d-fcd14f78d10f.png?v=1784486325"},{"product_id":"semaglutide-10mg-10-vials","title":"Semaglutide – 10 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e is the most extensively studied \u003cstrong\u003eGLP-1 receptor agonist\u003c\/strong\u003e — a single, highly selective incretin-pathway agonist that has become the reference standard against which newer dual and triple agonists are measured. It acts on appetite signaling, glucose-dependent insulin release and gastric emptying.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 68-week \u003cstrong\u003eSTEP 1\u003c\/strong\u003e obesity trial, participants on 2.4 mg recorded a mean \u003cstrong\u003ebody-weight reduction of 14.9%\u003c\/strong\u003e, versus 2.4% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e50%\u003c\/strong\u003e lost 15% or more of their body weight, and \u003cstrong\u003e69%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIts evidence base runs deep: in \u003cstrong\u003etype-2 diabetes\u003c\/strong\u003e (SUSTAIN 1) semaglutide cut HbA1c by \u003cstrong\u003e1.55 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e, and in the 17,604-patient \u003cstrong\u003eSELECT\u003c\/strong\u003e cardiovascular trial it reduced major cardiac events by \u003cstrong\u003e20%\u003c\/strong\u003e in adults with obesity and no diabetes\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the semaglutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107327715,"sku":"SM10-10","price":585.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-semaglutide-10-mg.png?v=1784483883"},{"product_id":"tirzepatide-10mg-10-vials","title":"Tirzepatide – 10 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107360483,"sku":"T10-10","price":695.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-10-mg_5a231e8d-90f2-47b8-8cea-72445ba77603.png?v=1784483897"},{"product_id":"retatrutide-6mg-10-vials","title":"Retatrutide – 6 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107393251,"sku":"RT7-A-10","price":592.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-6-mg_7196c897-4769-40b5-8b70-33486b98c8d3.png?v=1784483912"},{"product_id":"retatrutide-24mg-10-vials","title":"Retatrutide – 24 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107426019,"sku":"RT26-A-10","price":1300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-24-mg_32335b84-3387-4b33-976f-ee7b577e391b.png?v=1784483926"},{"product_id":"retatrutide-12mg-10-vials","title":"Retatrutide – 12 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107458787,"sku":"RT14-A-10","price":875.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-12-mg_201594c4-920a-449c-b976-13f37baa3953.png?v=1784483943"},{"product_id":"tirzepatide-30mg-10-vials","title":"Tirzepatide – 30 mg (10 Vials)","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107491555,"sku":"T30-10","price":980.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-30-mg_dc0010db-6ff2-480a-b90b-5f7218da5ed7.png?v=1784483957"}],"url":"https:\/\/qovigen.com\/collections\/bulk-offers.oembed","provider":"Qovigen Peptides","version":"1.0","type":"link"}